This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Align Tech (ALGN), AbCellera Biologics (ABCL) and Pulmonx (LUNG)

Tipranks - Tipranks - Fri May 1, 10:36AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Align Tech (ALGN), AbCellera Biologics (ABCL) and Pulmonx (LUNG) with bullish sentiments.

Claim 55% Off TipRanks

Align Tech (ALGN)

Stifel Nicolaus analyst Jonathan Block maintained a Buy rating on Align Tech today and set a price target of $210.00. The company’s shares closed last Thursday at $173.99, close to its 52-week low of $157.57.

According to TipRanks.com, Block is a 4-star analyst with an average return of 4.0% and a 46.8% success rate. Block covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems, Tandem Diabetes Care, and Elanco Animal Health. ;'>

Align Tech has an analyst consensus of Moderate Buy, with a price target consensus of $203.43, representing a 14.9% upside. In a report issued on April 16, Citi also initiated coverage with a Buy rating on the stock with a $240.00 price target.

See the top stocks recommended by analysts >>

AbCellera Biologics (ABCL)

In a report released today, Stephen Willey from Stifel Nicolaus maintained a Buy rating on AbCellera Biologics, with a price target of $7.00. The company’s shares closed last Thursday at $3.99.

According to TipRanks.com, Willey is a 4-star analyst with an average return of 8.8% and a 43.0% success rate. Willey covers the Healthcare sector, focusing on stocks such as Janux Therapeutics Inc, Compass Therapeutics, and Abeona Therapeutics. ;'>

AbCellera Biologics has an analyst consensus of Strong Buy, with a price target consensus of $8.33, representing an 114.7% upside. In a report issued on April 15, Truist Financial also maintained a Buy rating on the stock.

Pulmonx (LUNG)

In a report released today, Rick Wise from Stifel Nicolaus maintained a Buy rating on Pulmonx, with a price target of $2.50. The company’s shares closed last Thursday at $1.26.

According to TipRanks.com, Wise has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -2.7% and a 43.0% success rate. Wise covers the Healthcare sector, focusing on stocks such as Kestra Medical Technologies Ltd., GE Healthcare Technologies Inc, and Treace Medical Concepts. ;'>

Pulmonx has an analyst consensus of Strong Buy, with a price target consensus of $3.50, which is a 196.6% upside from current levels. In a report released today, Canaccord Genuity also reiterated a Buy rating on the stock with a $5.00 price target.

Read More on ALGN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).